Dramatic Improvement of a Massive Plexiform Neurofibroma After Administration of Selumetinib.

Pediatr Neurol

Pediatric Neuro-Oncology Unit, Pediatrics Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.

Published: April 2020

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pediatrneurol.2019.11.010DOI Listing

Publication Analysis

Top Keywords

dramatic improvement
4
improvement massive
4
massive plexiform
4
plexiform neurofibroma
4
neurofibroma administration
4
administration selumetinib
4
dramatic
1
massive
1
plexiform
1
neurofibroma
1

Similar Publications

The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden for hospitals and patients. We evaluated the bioavailability of a novel encapsulated oral ATO formulation in APL patients in first complete remission during standard-of-care consolidation.

View Article and Find Full Text PDF

Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread acceptability and demand by providers and potential users of LAIs, implementation has been extremely limited since the introduction of cabotegravir/rilpivirine, the first LAI for HIV treatment, in January 2021, and long-acting cabotegravir, the first LAI for HIV prevention, in December 2021. We report results of a provider survey, conducted by the HIV Medicine Association, which identified LAI implementation barriers related to health insurance processes, staffing and administrative support, drug costs and acquisition, and access for individuals who are uninsured.

View Article and Find Full Text PDF

Apolipoprotein A-IV and its derived peptide, T55-121, improve glycemic control and increase energy expenditure.

Life Metab

August 2024

National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

It is crucial to understand the glucose control within our bodies. Bariatric/metabolic surgeries, including laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB), provide an avenue for exploring the potential key factors involved in maintaining glucose homeostasis since these surgeries have shown promising results in improving glycemic control among patients with severe type 2 diabetes (T2D). For the first time, a markedly altered population of serum proteins in patients after LSG was discovered and analyzed through proteomics.

View Article and Find Full Text PDF

Biostimulants stimulate plant growth and tolerance to salinity stress, which creates unfavorable conditions for plant growth from emergence to harvest; however, little is known about their roles in triggering salt tolerance. Therefore, the study aimed to determine how applying a foliar plant-derived biostimulant (Aminolom Enzimatico® 24%) affects the growth (leaf area, biomass weight, root diameter, root fresh weight, and water-soluble dry matter), physiology (chlorophyll content, electrolyte leakage, cell membrane stability, and relative water content), and stomata of the lower and upper parts of leaves in radish plants ( L.) under salinity stress.

View Article and Find Full Text PDF

Preventing the progression of cirrhosis to decompensation and death.

Nat Rev Gastroenterol Hepatol

January 2025

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Ministerio de Sanidad, Madrid, Spain.

Two main stages are differentiated in patients with advanced chronic liver disease (ACLD), one compensated (cACLD) with an excellent prognosis, and the other decompensated (dACLD), defined by the appearance of complications (ascites, variceal bleeding and hepatic encephalopathy) and associated with high mortality. Preventing the progression to dACLD might dramatically improve prognosis and reduce the burden of care associated with ACLD. Portal hypertension is a major driver of the transition from cACLD to dACLD, and a portal pressure of ≥10 mmHg defines clinically significant portal hypertension (CSPH) as the threshold from which decompensating events may occur.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!